Spin-off News
Here you find a selection of press releases from Max Planck Innovation spin-offs.
19.05.2010
With the initiation of Phase I clinical studies for a compound for the treatment of neuropathic pain, Evotec will receive a milestone payment of EUR 2.0 million from Boehringer Ingelheim. More
03.05.2010
Epigenomics AG licenses biomarker for colorectal cancer blood test screening to Canadian Warnex Medical Laboratories. Warnex plans to launch the testing service in the next few months as the first laboratory in Canada. More
03.05.2010
Alnylam Pharmaceuticals, Inc. announced that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series, titled "Therapeutic Compositions." It is the 17th patent in 2010. More
19.04.2010
The FDA's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) for SuppreMol's lead product SM101, a recombinant human soluble Fcγ receptor IIb, for the treatment of Idiopathic Thrombocytopenic Purpura (ITP). More
06.04.2010
Capsulution has won a grant from the European Commission for its project „Virus Entry“. More
01.04.2010
AmVac AG has been granted a European patent for its Sendai platform technology for its subsidiary company AmVac Research GmbH. The innovative technology has been licensed by Max-Planck-Innovation. More
22.03.2010
Affectis Pharmaceuticals AG has raised €3.3M in the first tranche of a series D financing. LSP, Aescap Venture, KfW, Bayernkapital and EMBL Ventures were participating in the round. More
21.03.2010
Agennix AG raises € 9.8 million in private placement with existing shareholders. More
15.03.2010
MorphoSys granted further patent on its core antibody technology HuCAL in Japan. More
11.03.2010
Epigenomics AG Receives Allowance for Key Technology Patent on HeavyMethyl™ technology in Japan. More
10.03.2010
Evotec AG successfully completes the clinical part of the first Phase I study with EVT 103, a drug candidate intended for oral use in conditions such as treatment-resistant depression. More
24.02.2010
Anadys Pharmaceuticals' ANA598 demonstrates 73% cEVR in combination with interferon and ribavirin. More
23.02.2010
DeveloGen AG receives US$ 500.000 Funding from the Juvenile Diabetes Research Foundation for Beta Cell Research. More
22.02.2010
Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV01 in Adult Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) Infection. More
22.02.2010
Proteros and Axikin reach significant milestones with integrated drug discovery project. More
10.02.2010
First Milestone achieved in Phytowelt GreenTechnologies' research collaboration with Syngenta Flowers. More
01.02.2010
DIREVO Industrial Biotechnology Raises € 6 Million in financing round, which was led by TVM Capital and NRW.BANK. More
20.01.2010
Capsulution Pharma AG completes capital increase thus gaining more than € 750.000,00 of fresh capital. More
12.01.2010
Kinaxo extends its Collaboration with Roche, applying its phosphoproteomics technology PhosphoScout®. More
14.12.2009
Evotec AG achieves milestone in medicinal chemistry collaboration aimed at identifying novel inhibitors for a protease target with Ono Pharmaceutical Co., Ltd. More
10.12.2009
Kinaxo Biotechnologies GmbH receives, as part of a consortium, € 700,000 research grant from the Bavarian Research Foundation to fund the discovery of protein kinase inhibitors as potential therapies for the treatment of herpes viruses. More
03.12.2009
AmVac AG has joined forces with the long-term strategic investor V+ GmbH & Co Fonds 2 KG. The private equity company has invested CHF 1,500,000 in AmVac AG since the first half of 2009 and intends to acquire further shares worth CHF 3,000,000. More
02.12.2009
Agennix AG Announces Positive Results with Talactoferrin in Phase 2 Trial in Severe Sepsis. More
20.11.2009
KINAXO Biotechnologies GmbH Completes Financing Round to Enhance Biomarker Development. More
12.11.2009
MicroDiscovery and Bayer Schering Pharma renew their successful cooperation in the field of bioinformatics. More
09.11.2009
Scientists at DeveloGen AG receive Phoenix Science Award 2009 for a publication in the field of beta cell regeneration. More
09.11.2009
Evotec AG and Boehringer Ingelheim continue Research Collaboration for another 4 years at a value of EUR 15 million plus milestones and royalties. More
09.11.2009
MorphoSys AG receives regulatory approval to start phase 1b/2a clinical trial for ist lead drug MOR103, a fully human monoclonal antibody directed against Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF). More
22.10.2009
Evotec AG receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim. More
17.09.2009
Alnylam, Regulus and Isis Announce First microRNA Patent Grant in Japan from Tuschl III Patent Series. More
15.09.2009
Alnylam and Medtronic Present New Late-Stage Pre-clinical Data on ALN-HTT, an RNAi Therapeutic for the Treatment of Huntington's Disease. More
09.09.2009
Alnylam Announces Allowance in Europe of New Fundamental Patent in the Kreutzer-Limmer III Patent Series Broadly Covering RNAi Therapeutics in Oncology. More
09.09.2009
Evotec announces Research Agreement with Biogen Idec. More
08.09.2009
Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist. More
08.09.2009
MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma. More
07.09.2009
SuppreMol receives public research funding for its lead project SM101. More
25.08.2009
Epigenomics AG: Clinical Study Shows Lead Biomarker for Lung Cancer also works in Blood. More
12.08.2009
Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories. More
11.08.2009
Anadys Pharmaceuticals: ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis Patients. More
03.08.2009
Protagen closes new Round of Financing for the Development of molecular Diagnostics for Prostate Cancer and Multiple Sclerosis. More
29.07.2009
Evotec Receives Milestone Payment from Boehringer Ingelheim. More
08.07.2009
Alnylam Joins GSK in Donating Intellectual Property to Patent Pool for Neglected Tropical Diseases. More
News alert
Do you want to receive our newsletter and press releases?
Subscribe here
Media contact
Markus Berninger
Phone: (089) 290919-30